PURE Bioscience Statistics
Total Valuation
PURE Bioscience has a market cap or net worth of 6.60 million. The enterprise value is 11.50 million.
| Market Cap | 6.60M |
| Enterprise Value | 11.50M |
Important Dates
The last earnings date was Wednesday, October 29, 2025.
| Earnings Date | Oct 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PURE Bioscience has 111.89 million shares outstanding. The number of shares has increased by 0.01% in one year.
| Current Share Class | 111.89M |
| Shares Outstanding | 111.89M |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 41.25% |
| Owned by Institutions (%) | n/a |
| Float | 65.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.00 |
| PB Ratio | -1.29 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.80 |
| EV / Sales | 5.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.12
| Current Ratio | 1.12 |
| Quick Ratio | 0.86 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.60 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -151.39% |
| Return on Invested Capital (ROIC) | -1,385.37% |
| Return on Capital Employed (ROCE) | -1,893.33% |
| Revenue Per Employee | 183,500 |
| Profits Per Employee | -199,917 |
| Employee Count | 12 |
| Asset Turnover | 2.35 |
| Inventory Turnover | 9.13 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.25% in the last 52 weeks. The beta is 0.41, so PURE Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | -48.25% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.08 |
| Relative Strength Index (RSI) | 31.94 |
| Average Volume (20 Days) | 35,211 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.06 |
Income Statement
In the last 12 months, PURE Bioscience had revenue of 2.20 million and -2.40 million in losses. Loss per share was -0.02.
| Revenue | 2.20M |
| Gross Profit | 1.30M |
| Operating Income | -2.27M |
| Pretax Income | -2.40M |
| Net Income | -2.40M |
| EBITDA | -2.27M |
| EBIT | -2.27M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 334,000 in cash and 5.24 million in debt, giving a net cash position of -4.90 million or -0.04 per share.
| Cash & Cash Equivalents | 334,000 |
| Total Debt | 5.24M |
| Net Cash | -4.90M |
| Net Cash Per Share | -0.04 |
| Equity (Book Value) | -5.12M |
| Book Value Per Share | -0.05 |
| Working Capital | 109,000 |
Cash Flow
| Operating Cash Flow | -2.02M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 59.17%, with operating and profit margins of -103.18% and -108.95%.
| Gross Margin | 59.17% |
| Operating Margin | -103.18% |
| Pretax Margin | -108.95% |
| Profit Margin | -108.95% |
| EBITDA Margin | -103.09% |
| EBIT Margin | -103.18% |
| FCF Margin | n/a |
Dividends & Yields
PURE Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.01% |
| Shareholder Yield | -0.01% |
| Earnings Yield | -36.34% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 15, 2012. It was a reverse split with a ratio of 0.125.
| Last Split Date | Aug 15, 2012 |
| Split Type | Reverse |
| Split Ratio | 0.125 |
Scores
PURE Bioscience has an Altman Z-Score of -187.97 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -187.97 |
| Piotroski F-Score | 4 |